Journal of Drugs in Dermatology

View more issues:

Articles in July-August, 2004 issue of Journal of Drugs in Dermatology

• Telithromycin: a brief review of a new ketolide antibiotic
  by Noah Scheinfeld
• Etanercept approved for treatment of psoriasis
• Thalidomode as a potential treatment for scleromyxedema
• Characterizing serum protein patterns in selected skin diseases
• Influences
• Imiquimod: a potential weapon against morphea and fibromatoses
  by Mohammad Reza Namazi
• The use of sulfur in dermatology
  by Aditya K. Gupta
• Imiquimod receives nod from FDA for treatment of superficial basal cell carcinomas
• The effect of inositol supplements on the psoriasis of patients taking lithium: a randomized, placebo-controlled trial
• Topical retinoids
• Overview on desonide 0.05%: a clinical safety profile
  by Vicky Kwan Wong
• Impetigo herpetiformis in a primigravida: successful treatment with etretinate
  by Iqbal A. Bukhari
• Avanir completes Phase I study of experimental asthma/allergy drug
• Clinical features
• Concluding remarks
• Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel
  by Christopher Nelson
• A dramatic change in HIV treatment
  by Karl Wilkins
• Presentations at different stages
• Radiation therapy in treating patients with head and neck cancer
• A letter from the Editor-in-Chief
  by Perry Robins
• A double-blinded randomized trial testing the tolerability and efficacy of a novel topical agent with and without occlusion for the treatment of cellulite: a study and review of the literature
  by Jaggi Rao
• Imiquimod approved for treatment of actinic keratoses
• Treatment of cutaneous sarcoidosis with thalidomide
• Phase II randomized study of cultured skin substitutes versus split thickness skin grafts in patients with severe burn injuries
• Skin care
• Poly-L-lactic acid: a temporary filler for soft tissue augmentation
  by Birgit Woerle
• Elephantiasis nostrum verrucosa of the abdomen: clinical results with tazarotene
  by Jason Boyd
• FDA approves pain-patch lidocaine delivery system
• Photodynamic therapy in treating patients with skin cancer or solid tumors metastatic to the skin
• Incidence
• Laser treatment
• Corixa announces initiation of Phase I clinical trial of CRX-675
• Oral acyclovir for neonatal HSV disease of the skin, eyes, and mouth
• Examination of clinical and laboratory abnormalities in patients with defective DNA repair: xeroderma pigmentosum, Cockayne syndrome, or trichothiodystrophy
• Bioengineered skin and wound healing
• Hormones
• The acquisition of blood and skin samples from normal volunteers to support research activities on dermatologic diseases
• 5 alpha-reductase and finasteride in pattern alopecia and acne
  by Craig G. Burkhart
• Disseminate and recurrent infundibulofolliculitis: response to isotretinoin
  by K. Aroni
• FDA approves chewable antihistamine, Zyrtec , for children
• Tertiary contact vaccinia in a breastfeeding infant
• Combination treatments
• Improved quality of life with effective Treatment of Facial Melasma: the PIGMENT trial
  by R. Balkrishnan
• Treatment of pyoderma gangrenosum with etanercept
  by Joseph Wilson McGowan
• TransTech Pharma completes first Phase I clinical trial
• Celecoxib in preventing skin Cancer
• Office-based procedure
• Continuing care and treatment for patients with cancer/AIDS/skin disease
• Theodore B. Sutnick, MD
  by C. William Hanke
• Lichen planus pigmentosus presenting as diffuse facial melanosis
  by M.R. Namazi
• TKT begins clinical trial for Gaucher disease
• Tacrolimus ointment in the treatment of eyelid dermatitis
• Screening patients for NCI protocol eligibility
• Oral antibiotics
• Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis
  by Michael Jarratt
• Pustular psoriasis induced by infliximab
  by Marzieh Thurber
• FDA approves Nasacort HFA Nasal Aerosol for perennial and seasonal allergic rhinitis
• Evaluation and treatment of patients with dermatologic diseases